Serplulimab for Locally Advanced Cervical Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2026
This study is a randomized, controlled, open-label, phase II clinical trial designed to enroll patients with previously untreated locally advanced cervical cancer. The study aims to evaluate the efficacy and safety of adding chemotherapy to serplulimab combined with concurrent chemoradiotherapy. The primary endpoint of this study is progression-free survival (PFS).
Epistemonikos ID: a3bd84b3c1b1329d99b9d98ed599d2414b29af82
First added on: Jan 15, 2026